Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Iridex Corporation (IRIX) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer incorporated in Delaware with principal offices in Mountain View, California, Iridex uses SEC reports to present information on its ophthalmic laser business, financial condition, and material events.
Key documents for IRIX include Form 10‑K annual reports, which describe the company’s business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for glaucoma, diabetic macular edema (DME), and other retinal diseases. Form 10‑Q quarterly reports provide interim updates on revenues from consoles, delivery devices, consumables, services, and support activities, along with segment information for its ophthalmology operations.
Iridex also files Form 8‑K current reports to announce specific events. Recent 8‑Ks have covered preliminary financial results, quarterly earnings releases, participation in investor conferences, and Nasdaq listing compliance matters, including the company’s notification of non‑compliance with Listing Rule 5550(b) and subsequent confirmation that it regained compliance with the stockholders’ equity requirement.
Investors can further review registration statements, proxy materials, and insider transaction reports such as Form 4, where applicable, to understand equity ownership and governance. On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as non‑GAAP adjusted EBITDA reconciliations, stockholders’ equity, and risk factor disclosures, allowing users to navigate Iridex’s regulatory history more efficiently.
IRIDEX Corporation reported an insider share purchase by its Chief Financial Officer. On 11/14/2025, the CFO acquired 14,769 shares of common stock in an open market purchase coded "P" at a price of $0.88 per share. Following this transaction, the officer beneficially owned 76,719 shares of IRIDEX common stock held directly. This type of report provides transparency about trading activity by senior management in the company’s equity.
IRIDEX (IRIX) reported Q3 2025 results showing total revenues of $12.484M, up from $11.581M a year ago. Gross profit was $4.013M versus $4.323M last year, with a loss from operations of $1.411M improving from $1.870M. Net loss narrowed to $1.573M from $1.933M, as operating expenses declined year over year.
By product, Retina delivered $6.698M and Cyclo G6 $3.537M. The United States contributed $5.588M; EMEA reached $4.033M. A key distributor, Topcon, accounted for 31% of Q3 revenues.
Cash and cash equivalents were $5.573M at quarter‑end (vs. $2.387M at December 28, 2024), aided by $6.0M of Series B convertible preferred stock and a $4.0M convertible note, partially offset by repayment of a prior note. The company recorded a year‑to‑date loss on extinguishment of debt of $1.335M and an inventory write‑down of $0.823M. Deferred revenue ended at $9.416M, including exclusivity fees recognized at $0.4M in Q3.
Total stockholders’ equity increased to $4.681M from $2.097M. Common shares outstanding were 17,189,981 as of November 6, 2025.
Patrick Mercer, President and CEO of IRIDEX CORP (IRIX), reported a sale of 23,850 shares on 10/01/2025 at a reported price of $1.13 per share. After the transaction Mercer beneficially owns 392,007 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 09/12/2025. The Form 4 shows two non-derivative acquisitions: 250 shares at $1.37 and 1,200 shares at $1.36, for a total of 1,450 shares acquired. Following the transactions, the filing reports 61,950 shares beneficially owned. The form is signed by an attorney-in-fact on 09/15/2025.
Romeo R. Dizon, the Chief Financial Officer and a director of Iridex Corp (IRIX), reported insider purchases on 09/10/2025. He acquired 1,000 shares at $1.33 and 500 shares at $1.36, bringing his total reported beneficial ownership to 59,250 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025.
Iridex Corp (IRIX) insider purchase: Chief Financial Officer Romeo R. Dizon purchased 1,500 shares of Iridex common stock on 09/09/2025 at a price of $1.37 per share. Following the transaction, the reporting person beneficially owns 57,750 shares. The Form 4 was filed indicating the transaction code "P" and was signed by an attorney-in-fact on 09/10/2025.
IRIDEX Corporation reports that it has regained compliance with Nasdaq’s continued listing standards. Based on its Form 10-Q for the quarter ended June 28, 2025, the company now meets the Nasdaq Listing Rule 5550(b)(1) minimum stockholders’ equity requirement of $2,500,000 for the Nasdaq Capital Market.
Nasdaq has informed IRIDEX that the prior non-compliance matter is closed, removing the earlier listing deficiency. The company also issued a press release on September 9, 2025 to highlight its renewed compliance with the stockholders’ equity requirement.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported an insider purchase of common stock. On 09/08/2025 he acquired 500 shares at $1.40 per share, increasing his reported beneficial ownership to 56,250 shares. The Form 4 was signed on 09/09/2025 by an attorney-in-fact.
Iridex Corp (IRIX) insider purchase reported: Chief Financial Officer Romeo R. Dizon acquired 1,000 shares of Iridex common stock on 09/05/2025 at $1.35 per share, increasing his beneficial ownership to 55,750 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025. No derivative transactions or additional details were reported.
Iridex Corp (IRIX) Form 4: Romeo R. Dizon, identified as the Chief Financial Officer, reported three transactions on 09/04/2025. The filing shows acquisitions of 404, 96, and 625 common shares at prices of $1.32, $1.345, and $1.39 respectively. After those transactions the filing lists beneficial ownership totals of 54,029, 54,125, and 54,750 shares. The form was signed by an attorney-in-fact on 09/05/2025.